Publicaciones en colaboración con investigadores/as de VU University Medical Center (46)

2023

  1. Uncertainties and controversies in axillary management of patients with breast cancer

    Cancer Treatment Reviews, Vol. 117

2022

  1. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

2020

  1. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

    Acta Neuropathologica

  2. Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Carbon dioxide embolism associated with transanal total mesorectal excision surgery: A report from the international registries

    Diseases of the Colon and Rectum, Vol. 62, Núm. 7, pp. 794-801

  2. Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia

    Scientific Reports, Vol. 9, Núm. 1

  3. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia

    Nature Medicine, Vol. 25, Núm. 1, pp. 152-164

  4. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

2018

  1. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes

    Breast Cancer Research and Treatment, Vol. 168, Núm. 1

  2. Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes (Breast Cancer Research and Treatment, (2018), 168, 1, (1-12), 10.1007/s10549-017-4598-5)

    Breast Cancer Research and Treatment

  3. Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel

    Journal of Hematology and Oncology, Vol. 11, Núm. 1

  4. Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies

    PLoS Medicine, Vol. 15, Núm. 1

  5. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  2. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv52-iv61

  3. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448

  4. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017

  5. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    The Lancet Oncology, Vol. 18, Núm. 4, pp. e206-e217

  6. Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

    Haematologica